Amplification of the c-er bB-2 gene (located on 17q11.2-12) is accompanied by overexpression of its cell surface receptor product, p185
The human proto-oncogene c-erb B-2 (also called HER-2 and neu) encodes a 185kd transmembrane phosphoprotein (p185 ERBB2 ) related to the epidermal growth factor receptor, which has tyrosine kinase activity. Although p185 ERBB2 is a receptor for a still poorly characterized growth ligand, it is assumed to be involved in the regulation of cell growth and differentiation (1) . Increased p185 ERBB2 expression is associated with malignant cell transformation (2) . Interest in the clinical application of c-erbB-2 was initially stimulated by the work of Slamon et al. (3) , who showed that amplification of this gene in breast cancer correlated significantly with both time to relapse and overall survival. In their subsequent study, they found almost complete concordance between the gene amplification detected by Southern blot analyses and the overexpression as determined by Northern blot, Western blot and/or immunohistochemical analyses (4) . Since then, most, but not all, investigators have found that either amplification or increased expression of the c-erbB-2 gene correlates with poor prognosis in many different human primary tumors including ovarian (5) , pulmonary (6) and endometrial carcinomas (7) . In non-small cell lung carcinomas (NSCLCs), some investigators reported that more than half of the tumors overexpressed the oncoprotein (8) ; however, according to others, its frequency was less than 2% (9) . Previous Southern blot studies raised the frequency of zero to several percent (10 -13) . The discordance between the frequencies of c-erbB-2 overexpression, and overexpression and gene amplification in NSCLCs may be attributed to quantitatively and/or qualitatively different mechanisms of gene amplification from those in other carcinomas.
Fluorescence in situ hybridization (FISH) is a potent tool to investigate not only numeral aberration, but also the amplification status of genes in interphase nuclei. Applying this technique to formalinfixed, paraffin-embedded tissues, we clarified that in gastric adenocarcinomas, high-level amplification of c-erbB-2 principally in homogeneously staining regions (HSRs) control overexpression of the protein in the cytoplasmic membrane (14, 15) . In the present study, we compared the findings of immunohistochemistry and FISH to clarify c-erbB-2 aberrations in primary lung cancers. To the best of our knowledge, this is the first study that examined the c-erbB-2 status in the primary lung cancers by FISH. Recently, new adjuvant chemotherapy using an anti-c-erbB-2 antibody was being tested in clinical trials (16) . Therefore, it is crucial to identify patients whose tumors respond to the agent. The use of FISH and interphase cytogenetics may be useful in the management of such patients.
MATERIALS AND METHODS

Tissue Samples
We examined 195 pulmonary carcinomas consecutively resected at the Department of Surgery, Yamanashi Medical University between 1983 and 1999. There were 182 primary lung cancers (147 adenocarcinomas, 24 squamous cell carcinomas, 5 large cell carcinomas, 6 small cell carcinomas) and 13 metastatic cancers from the colon (9), breast (3) and stomach (1).
Histology and Immunohistochemistry
Serial sections (4 m) that had been cut from representative formalin-fixed, paraffin-embedded cancer tissue and placed onto silanated glass slides (Matsunami, Tokyo, Japan) were used for hematoxylin-eosin staining, immunohistochemical detection of the c-erbB-2 protein and FISH analysis. The immunohistochemical study was carried out with a polyclonal antibody (Nichirei, Tokyo, Japan; working dilution, 1:100), which recognizes the internal domain of the human c-erbB-2 protein. Antibody binding was visualized by the avidin-biotinperoxidase complex procedure. The specificity of the antibody and validity of the methodology were verified by our previous studies on gastric cancers (14, 15) .
All slides were reviewed by three pathologists (NH, TY, AO), who were unaware of the gene amplification. Each slide was scored according to the following scale: Ϫ, no discernible staining or, at most, faint, background-type staining; 1ϩ, faint staining with a discernible but incomplete plasma membrane pattern and/or unequivocal cytoplasmic staining; 2ϩ, unequivocal membrane staining with moderate intensity; 3ϩ, strong and complete plasma membrane staining. This score is basically similar to those used for breast cancers (17, 18) except 1ϩ. Many studies have chosen to ignore the cytoplasmic staining (18, 19) ; however, we tentatively included this in 1ϩ, because it was virtually impossible to differentiate faint membranous staining from cytoplasmic staining in several cases and to compare previous findings using similar standards.
FISH
FISH analysis was applied to all immunostainingpositive tumors and the negative tumors selected at random. Numerical changes affecting chromosome 17 and the c-erbB-2 gene locus were determined using the fluorescently labeled DNA probes purchased from Vysis, Inc (Downers Grove, IL). The HER-2/neuSpectrumOrange probe contains DNA sequences specific for the HER-2/neu human gene locus and hybridizes to region 17q11.2-q12 of human chromosome 17. The CEP 17 (chromosome enumeration probe 17)/SpectrumGreen probe contains alphasatellite DNA that hybridizes to the D17Z1 locus (centromere region of chromosome 17). The probes were provided predenatured and premixed in hybridization buffer. The CEP 17 probe was used as the control to determine the copy number for chromosome 17. Removal of protein from the tissue sections was conducted as previously described (14, 15) . In brief, deparaffinized and rehydrated tissue sections mounted on silanated slides were incubated in 20% sodium bisulfite/2ϫ standard saline citrate at 43°C for 20 minutes. After washing in 2ϫ SSC, the slides were treated with proteinase K (25 ng/mL) (BoehringerMannheim, Mannheim, Germany) at 37°C for 30 minutes. Denaturation, hybridization, and posthybridization were carried out according to the manufacturer's protocol. The tissue sections were counterstained with 4', 6-diamidine-2'-phenylindole dihydrochloride (DAPI) in an antifade solution (Oncor, Gaithersburg, MD) and examined with an epifluorescence microscope (Olympus, Tokyo, Japan) equipped with Triple Bandpass Filter sets (Vysis) for DAPI, SpectrumOrange and SpectrumGreen. Copy numbers for centromere 17 and c-erbB-2 signals were counted, respec-tively, in at least 20 cancer nuclei and 200 noncancerous cells, according to the method of Persons et al. (20) . For each tumor the ratio of the c-erbB-2 signals to centromere 17 signals were calculated. Cells were scored only when at least one bright centromeric and one c-erbB-2 signals in a distinct nuclear border were present. When c-erbB-2 signals coalesced to clusters, FISH images were taken with a CCD camera (Photometrics, Tucson, AZ) and the copy number was calculated by comparing signal intensities of clusters and single copies using IPLab Scientific imaging software (Scanalytics Inc, Fairfax, VA). Furthermore, according to the centromere 17 number of the predominant population, tumors were arbitrarily classified as different ploidy of chromosome 17: tumors were classified as disomic, trisomic, or tetrasomic if more than 50% of nuclei contained two, three, or four copies of centromeric signals, respectively. When the proportion of cells with negative nuclei exceeded 20%, the procedure was regarded as suboptimal and repeated once or abandoned. The FISH images were taken using photographic camera and recorded on film slides.
RESULTS
Immunohistochemistry
Positive immunostaining of c-erbB-2 protein was found in 26 (13.3%) of the 195 pulmonary carcinomas analyzed. One well-differentiated adenocarcinoma (Case 1) (Fig. 1A) and a metastatic carcinoma from the breast (Case 26) (Fig. 1B) showed a 3ϩ staining pattern, and a large cell carcinoma showed a 2ϩ staining as shown in Figure 2 . In these three tumors, most cancer cells were c-erbB-2 positive and there was no intratumoral heterogeneity in the gene expression. In the other 23 primary pulmonary cancers the reaction products was found faint as shown in Figure 3 , and were judged as the 1ϩ pattern. In these tumors, uneven distribution of the positive cells in the tumor was often found. In the remaining 169 tumors, including all 6 SCLCs, no immunostaining was found. The histopathologic findings of the 26 positive cases are summarized in Table 1 . Table 1 .
In the adenocarcinoma (Case 1) and the large cell carcinoma (Case 25), immunostained 3ϩ and 2ϩ, respectively, cancer cells typically had one or occasionally two clusters of the c-erbB-2 signals as shown in Figure 4 . The precise enumeration was impossible in most cancer cells due to the tight coalesced signals, but image analysis of each cluster showed approximately 20-fold stronger fluorescence as single copy signals. In the metastatic cancer from the breast (Case 26), immunostained 3ϩ, cancer cells had less tightly coalesced clusters and scattered signals as shown in Figure 5 , and the c-erbB-2 copy number per nucleus was 24.2 Ϯ 13.4 (mean Ϯ SD). (In this case similar amplification and 3ϩ immunostaining were found in the primary tumor of the breast.) Among the nineteen 1ϩ tumors, three cases (Cases 12, 14, and 21) had several (maximum 5) signals in addition to the centromeric signals as shown in Figure 6 . Normal bronchial epithelial cells and non-neoplastic stromal or inflammatory cells associated with the tumors had one or two centromere 17 and c-erbB-2 signals. The ratio of c-erbB-2 signals to centromere 17 signals of the non-neoplastic cells was 1.10 Ϯ 0.42 (mean Ϯ SD). Using the Kruskal-Wallis test, six tumors (Cases 1, 12, 14, 21, 25, and 26) had significantly higher (P Ͻ 0.01) ratios than this figure and were considered amplification positive. Three tumors (Cases 1, 25, and 26) with mean amplification ratios more than 8-fold were classified as high-level amplification tumors and those (Cases 12, 14, and 21) with ratios less than three were regarded as low-level amplification tumors.
DISCUSSION
In the present study, we found various levels of immunoreactivity of c-erbB-2 in 25 (14.2%) of 176 NSCLCs, and no positive tumors in 6 SCLCs. Although there is general agreement that there are no c-erbB-2 positive SCLCs, the frequency of c-erbB-2 positivity among NSCLCs is still controversial. This is mainly because variable criteria have been used to interpret the results of immunohistochemistry. Kern # Copy number of c-erbB-2 was calculated by image analyzer. Furthermore, in most studies on breast cancer using a four-tier grading system to evaluate immunohistochemistry, which appeared similar to that of the present study except for 1ϩ, only 2ϩ and 3ϩ stainings are considered as meaningful because they are accompany unequivocal gene amplification (17, 18) . In the present study, definite membranous staining was found in only two (1.2%) of 176 NSCLCs and its frequency corresponded to that reported by McCann et al. (9) . Furthermore, it was in the two primary, and one metastatic cancer with 3ϩ staining that a definite high-level c-erbB-2 amplification was found by FISH. The two primary cancers showed cancer nuclei with one or two clustered signals, which corresponded to the FISH image of interphase nuclei with amplified genes in HSR (14, 15) . The FISH image of loose clusters with scattered signals found in the metastatic cancer from the breast may represent complex translocations of the amplified genes in HSR to other chromosomes, which have been demonstrated in several breast cancer cell lines (21) . This is consistent with the present assumption based on our previous FISH studies on gastric cancer that high-level amplification principally produces the c-erbB-2 gene HSR form and controls overexpression of the protein in the cytoplasmic membrane (14, 15) .
Before introduction of the FISH technique, c-erbB-2 amplification was detected using Southern blot hybridization. Several Southern blot hybridization studies have examined the c-erbB-2 amplification in NSCLCs, unfortunately none were comparative studies with protein overexpression (10 -13). Shiraishi et al. (10) found c-erbB-2 amplification in only one of 51 primary NSCLCs (one in 21 adenocarcinomas), Cline and Battifora (11), 1 in 27 (1 in 16 adenocarcinomas) and Schneider et al. (12) , 2 in 60 (one adenocarcinoma and one squamous cell carcinoma). Slebos et al. (13) , however, reported no tumors in 21 adenocarcinomas examined. The levels of the amplification also varied: 4-fold in one case, 6-fold in one case, and 20-fold in two cases. The levels of amplification detected by Southern blotting were not infrequently lower than those seen by FISH because in solid tumors such as lung cancer the extracted tumor DNA is always diluted by DNA of noncancerous tissue. Another pitfall in detecting gene amplification by Southern blotting is that the quantitation of amplification relates to the reference marker. Thus, it is occasionally difficult to distinguish lowlevel gene amplification from an excess of gene copies secondary to aneusomy by conventional Southern blot analysis (14) . It is also difficult to differentiate the two categories by FISH analysis using tissue sections, because when cutting 4 microns into a 10 to 15 micron nucleus, unavoidable signal heterogeneity is caused by nuclear truncation. Thus, analysis of adequate numbers of nuclei within a specimen to correct for this potential problem should be done (22) . Recently, the feasibility of enumerating two-color FISH signals in 20 nuclei on tissue sections was demonstrated by statistical analysis (20) . Therefore we believe that in this study, such artifacts were considerably reduced, and that the numerical changes found in three tumors (Cases 12, 14, and 21) were low-level amplifications, rather than increases due to polysomy. Although the molecular genetic mechanisms of such low-level amplification are unknown at present, these low-level amplifications do not translate into definite protein overexpression.
In addition to investigating carcinogenesis and giving prognosis for cancer patients, clarification of expression and amplification of c-erbB-2 is having a new impact on cancer treatment. Recently, a recombinant humanized antibody against the extracellular domain of c-erbB-2 (Trastuzumab) was approved for the treatment of solid tumors. Also, the United States Food and Drug Administration approval was granted on the basis of findings on the use of the agent in the treatment of a subset of patients with metastatic breast cancer overexpressing the c-erbB-2 (23). Although they are very rare, pulmonary carcinomas with high overexpression levels in the cellular membrane due to gene amplification, supposedly due to the same mechanism functioning in breast cancer, may be more efficiently treated by this therapy than other pulmonary carcinomas.
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